Investor Alert

New York Markets Open in:

Revolution Medicines Inc.



After Hours

 --Quotes are delayed by 20 min

Sep 20, 2023, 6:26 p.m.





-0.22 -0.74%


Volume 21,173

Quotes are delayed by 20 min


Previous close

$ 31.00

$ 29.73


-1.27 -4.10%

Day low

Day high




52 week low

52 week high




Sushil Patel

Sushil Patel is on the board of Revolution Medicines, Inc. and Chief Strategy Officer of Replimune Group, Inc.

Dr. Patel previously held the position of Vice President-Franchise & Head-Oncology at Genentech, Inc.

Dr. Patel received a graduate degree from Imperial College London, a doctorate from the University of London and an undergraduate degree from the University of Warwick.


Date Shares Transaction Value
06/08/2023 5,200   Award at $0 per share. 0
06/16/2022 10,500   Award at $0 per share. 0

Officers and Executives

Dr. Mark A. Goldsmith
Chairman, President & Chief Executive Officer
Dr. Margaret A. Horn
Chief Operating Officer
Mr. Jack Anders
Chief Financial Officer
Dr. Stephen M. Kelsey
President-Research & Development
Dr. Walter Reiher
Chief Information Officer
Dr. Xiao Lin Wang
Executive Vice President-Clinical Development
Mr. Daniel Simon
Chief Business Officer
Ms. Linnet Zia
VP-Strategy, Financial Planning & Analysis
Ms. Luan M. Wilfong
Chief Human Resources Officer
Mr. Jeff Cislini
Secretary, Senior Vice President & General Counsel
Dr. Flavia Borellini
Independent Director
Dr. Sushil Patel
Independent Director
Dr. Lorence H. Kim
Independent Director
Ms. Elizabeth McKee Anderson
Independent Director
Mr. Alexis A. Borisy
Lead Independent Director
Dr. Thilo Schroeder
Independent Director
Dr. Barbara L. Weber
Independent Director
Link to MarketWatch's Slice.